BackPhaseBio Pharmaceuticals Overview

PhaseBio Pharmaceuticals Other Assets

Latest other assets for PHAS: $0.

Get informed when a big investor buys or sells

+ Follow
Other Assets
$0.00

Peer trimmed avg / median

Loading

PhaseBio Pharmaceuticals Other Assets History

Loading

PhaseBio Pharmaceuticals vs. peers: Other Assets Comparison

Loading

PhaseBio Pharmaceuticals Other Assets Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

PhaseBio Pharmaceuticals (PHAS) FAQ

As of the most recent data (June 2022), PHAS shows a other assets of $0. In the prior-year period, the figure was $0. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, PHAS's other assets is now $0 (was $0). Pairing that YoY change with peer averages gives a clearer picture of whether PhaseBio Pharmaceuticals is outperforming or lagging.

Tracking PHAS's other assets over time shows whether PhaseBio Pharmaceuticals is scaling, shrinking, or reshaping that part of the business. The current reading is $0 In the prior-year period, the figure was $0. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this other assets page, Stockcircle has PhaseBio Pharmaceuticals's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect other assets (currently $0) with ownership activity and broader fundamentals.

PhaseBio Pharmaceuticals's other assets is $0; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.